Open Nav

Aro Biotherapeutics

Raise awareness of company and technology platform in anticipation of Series A financing

  • Date:Wednesday, October 17
  • Time:2:15 PM - 2:30 PM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Aro Biotherapeutics is focused on developing breakthrough medicines from protein design to patients. Our proprietary Centyrin technology platform is based on protein engineering which creates simple, small, stable, selective, and soluble proteins that can be customized as bi, tri, or multispecific targeting agents. Centyrins can deliver a variety of payloads, including chemotoxins, nucleic acids for gene-modification or, peptides, and other "undruggable drugs".
  • Company
  • Company HQ City:Philadelphia
  • Company HQ Country:United States
  • Company HQ State:Pennsylvania           
  • CEO/Top Company Official:Sue Dillon, PhD
  • Year Founded:2017
  • Main Therapeutic Focus:Platform for Therapeutics
  • Lead Product in Development :Bi-specific Centyrin for NSCL and SCCHN cancers
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :multiple
  • Additional Information/Comments:Aro was spun out of Janssen Pharmaceuticals in January 2018, and received seed funding from JJDC. We have raised Centyrins for over 50 targets, and have world wide, exclusive rights, as well as granted IP, for the Centyrin platform. We have set out to build a proprietary pipeline of oncology assets, and plan to compliment our pipeline via partnerships with other biotech and pharmaceutical companies. Our strategy includes licensing Centyrins, and in certain cases, we are looking to co-develop assets in specific disease areas. We have a seasoned management team, with a tremendous track record in developing and launching biologics globally.
  • Previous and Current Investors:JJDC, undisclosed
  • Size of Last Investment Round:3 million
  • Total Amount Raised to Date, In All Rounds:13 million